HURA
Price:
$1.98
Market Cap:
$100.77M
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Industry
Biotechnology
IPO Date
2013-02-22
Stock Exchange
NASDAQ
Ticker
HURA
According to TuHURA Biosciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.68. This represents a change of -98.42% compared to the average of -169.16 of the last 4 quarters.
The mean historical PE Ratio of TuHURA Biosciences, Inc. over the last ten years is -0.43. The current -2.68 PE Ratio has changed 62.40% with respect to the historical average. Over the past ten years (40 quarters), HURA's PE Ratio was at its highest in in the June 2024 quarter at 0. The PE Ratio was at its lowest in in the September 2024 quarter at -666.80.
Average
-0.43
Median
-0.07
Minimum
-3.52
Maximum
-0.01
Discovering the peaks and valleys of TuHURA Biosciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.36%
Maximum Annual PE Ratio = -0.01
Minimum Annual Increase = -67.99%
Minimum Annual PE Ratio = -3.52
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -3.52 | 2.36% |
| 2023 | -0.14 | 320.19% |
| 2022 | -0.03 | -66.34% |
| 2021 | -0.10 | 130.73% |
| 2021 | -0.04 | 94.85% |
| 2020 | -0.02 | 92.32% |
| 2019 | -0.01 | -67.99% |
| 2018 | -0.04 | -62.53% |
| 2017 | -0.10 | -64.79% |
| 2016 | -0.28 | 71.14% |
The current PE Ratio of TuHURA Biosciences, Inc. (HURA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-1.23
5-year avg
-0.77
10-year avg
-0.43
TuHURA Biosciences, Inc.’s PE Ratio is less than Seer, Inc. (-1.36), less than VistaGen Therapeutics, Inc. (-2.46), less than Opus Genetics, Inc. (-2.43), less than Agenus Inc. (-0.69), greater than Cognition Therapeutics, Inc. (-3.40), less than Seres Therapeutics, Inc. (29.07), greater than Spero Therapeutics, Inc. (-2.93), less than Acumen Pharmaceuticals, Inc. (-0.90), less than Tevogen Bio Holdings Inc. (-2.66), less than Inovio Pharmaceuticals, Inc. (-0.00),
| Company | PE Ratio | Market cap |
|---|---|---|
| -1.36 | $107.12M | |
| -2.46 | $140.27M | |
| -2.43 | $153.73M | |
| -0.69 | $137.64M | |
| -3.40 | $129.50M | |
| 29.07 | $157.07M | |
| -2.93 | $128.44M | |
| -0.90 | $119.94M | |
| -2.66 | $83.79M | |
| -0.00 | $108.25M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like TuHURA Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like TuHURA Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is TuHURA Biosciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for TuHURA Biosciences, Inc. (HURA)?
What is the highest PE Ratio for TuHURA Biosciences, Inc. (HURA)?
What is the 3-year average PE Ratio for TuHURA Biosciences, Inc. (HURA)?
What is the 5-year average PE Ratio for TuHURA Biosciences, Inc. (HURA)?
How does the current PE Ratio for TuHURA Biosciences, Inc. (HURA) compare to its historical average?